Nicholas Ashton

🚨 In this paper in @NatureCommuniations, we find that Down syndrome #Alzheimer exhibits unique pathological features compared with sporadic late-onset and autosomal dominant AD with important implications for treatment strategies. nature.com/articles/s4146…

"Clocks" that relate amyloid and tau PET to time were used to examine the timing of biomarker changes (including plasma biomarkers) in Alzheimer disease. Plasma Aβ42/40 changes very early! onlinelibrary.wiley.com/doi/10.1002/an… #ENDALZ @FNIH_Org

We developed a #CSF assay for #SV2A and found it correlates strongly with UCB-J PET in Alzheimers—more so than other established CSF synaptic markers. A promising step toward fluid biomarkers of #synaptic density #biomarkers #neurodegeneration pubmed.ncbi.nlm.nih.gov/40491249/

NPTX2 is emerging as a key neurodegeneration biomarker, but measurement tools are limited. We developed a low-volume, automated Simoa assay for its quantification in CSF #biomarkers #neurodegeneration pubmed.ncbi.nlm.nih.gov/40522075/

Fluid biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay @AlamarBio @andrealessa alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…

Biomarkers of AD-related #neuroinflammation are missing from our toolbox for patient evaluation and research. This great work by @andrealessa start to see a change in that tide. alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…

I’m proud to share the first PhD paper of my first (formally) PhD student Ilaria Pola, where we investigated proteins associated with TSPO PET imaging. 🥳 We are now already working on the extension of this work, so stay tuned! 🧠💧🩸 @NicholasAshton @mcgillu

There she goes....😢 The Goodison montage on Football Focus #Everton

Immunoassay choice for #pTau217 is important! In this study, we show that LMW #pTau217 is more specific to Alzheimers pathology than HMW #pTau217 immunoassay designs – which can give false-positives. alz-journals.onlinelibrary.wiley.com/doi/10.1002/al… @biofinder_study @OskarHansson9

The boss is in town! 🇸🇪 Come and join our free lecture with Professor Henrik Zetterberg, the world leader in biomarkers for hashtag #Alzehimers disease, hosted at the @ASUBiodesign and @BannerHealth on Monday 28th April!

Our comments on the new #blood tests for #Alzheimers #disease which are increasingly improving and becoming applicable to clinical use. We should use them but use them in the correct way. nature.com/articles/d4158…

📢Our latest study, now published in @NatureMedicine , explores the potential of blood biomarkers on an automated platform to detect #Alzheimers . Plasma p-tau217 showed remarkable accuracy, with AUCs ranging from 0.93-0.96! 🩸🧠 Read more here: nature.com/articles/s4159…

New manuscript alert! Can blood-based biomarkers measured on a fully automated platform accurately identify Alzheimer’s disease (AD) pathology?🩸 Our new multi-cohort study has now been published in @NatureMedicine: nature.com/articles/s4159…. A thread🧵

Big, big thanks to all collaborators and co-authors, especially the Gothenburg, Barcelona, and Brescia teams! @SebastianPalmqv @ncjwarmenhoven @NicholasAshton @M_SuarezCalvet @OskarHansson9 @biofinder_study

We're entering a new era of #Alzheimers blood testing—fully automated platforms now deliver fast, accurate #pTau217 results for use in primary & secondary care. Proud to share senior authorship and proud of this multi-centre European collaboration. 🔗 nature.com/articles/s4159…

First panel of the DxA Day focuses on the current diagnostic landscape for Alzheimer’s - from development to implementation, featuring an expert panel les by @NicholasAshton of @BannerHealth. CC @OskarHansson9, @C2NDiagnostics, @washumedicine, @BCILifeSciences and @biogen

It was a tremendous honor to receive the Young Investigator Award from La Fondation Recherche Alzheimer (@Alzh_Fondation) earlier this month, in Paris. I am grateful for the recognition and inspired to receive my award alongside Professor Christian Haass

[#RECHERCHE #ALZHEIMER] 🧠 Clariane remet le Prix Européen Jeune Chercheur 2024 d’@Alzh_Fondation à @NicholasAshton pour ses travaux sur le développement de tests sanguins permettant un #diagnostic ➕ précoce de la maladie. 👉 clariane.com/espace-presse/… #biomarqueurs…

and now the paper is out... pubmed.ncbi.nlm.nih.gov/39907496/ 📣 33 different ways to measure #blood #pTau 👉Mass Spec, semi & fully-auto immunoassays 🩸#pTau217 consistently best 📈Corr. between #pTau217 assays = optimism for standardisation @jmschott @AshviniKeshavan @wagnersbrum

New *open access* paper in @alzdemjournals — with the @alzassociation #GBSC we compared 33 different plasma p-tau assays. TLDR — Plasma p-tau217 on several platforms was the best at discriminating Alzheimer’s from controls alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…